Business Wire

Trinité-Sur-Mer Celebrates the Launch of the Class40 IBSA

12.9.2022 13:00:00 EEST | Business Wire | Press release

Share

A real celebration was held on September 9 in the port of La Trinité-Sur-Mer, in Brittany, for the launch of the Class40 IBSA , the brand new boat with which Alberto Bona will participate in the Route du Rhum . The transatlantic regatta is indeed the first project of the three-year program Sailing into the Future. Together that the ocean sailor started with IBSA at the beginning of 2022.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220908006032/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Class40 IBSA: official launch. From left to right: Sidney Gavignet, Alberto Bona, Arturo Licenziati, Giorgio Pisani, Fabrice Jover (Photo: © IBSA | Beppe Raso)

Great enthusiasm and emotion characterised the event, that took place in the small but famous Breton port, along whose mooring quays are berthed some of the most prestigious trimarans that have gone around the world and have made the history of ocean sailing. And right here, Arturo Licenziati – President and CEO of the IBSA Group – Alberto Bona and his entire team celebrated the launch of an innovative and revolutionary hull, as well as the visionary project that supports it.

Sailing into the Future. Together is the three-year international project that we strongly pursued, because it combines several elements that for us are extremely important and distinctive: innovation, technology, commitment to sport and to the community, environmental and social responsibility”, commented Arturo Licenziati. “The whole project and this first great sporting challenge that we are preparing to face give us the opportunity to introduce to the world our vision, values ​​and Pillars (Person, Innovation, Quality and Responsibility), the same ones that we share with sport, and with sailing in particular.”

To break the bottle on the hull – in one of the most traditional rites of the nautical world, which officially baptises the boat – will be the godmother Francesca Licenziati, niece of IBSA’s President. The launch celebration is a moment of great pride and joy, shared by the whole team, who for months worked hard on the new boat and collaborated on several fronts, concretely showing how Sailing into the Future. Together is an international project, which involves Switzerland, France and Italy in particular, and is based on strong values ​​of inclusiveness, sustainability and teamwork.

After the technical launch on August 3, the hull designed by Sam Manuard – built by the shipyard JPS Production and hoisting the burgee of the Bellano Yacht Club – has been subject to a series of tests at sea, which allowed Alberto Bona to qualify for the Route du Rhum by sailing, between August 30 and September 5, the first 1,200 miles alone. The navigation took place in the Bay of Biscay, between Brittany and Spain, and highlighted the qualities of the hull and an excellent state of preparation in even complex weather conditions, with the winds and waves typical of the Atlantic Ocean.

After the technical launch”, said Alberto Bona, “we had very good feedback from every perspective, from the construction of the hull to the sails, from the design to the preparation of the team. We worked to prepare the Class40 IBSA as best, and by the end of August we were ready for the qualification: on this front, we accelerated as much as possible, because after a very hot and dry summer, we had signs that the weather conditions in the Northeast Atlantic were rapidly changing.

The Class40 IBSA thus already arrived at its launch with over 1,200 miles at sea and the first, exciting occasion of solitary navigation by Alberto Bona.

These have been even more beautiful days than I could have imagined: on the one hand the satisfaction of now being in perfect timing for the Route du Rhum, considering that we only started the project last February; on the other the certainty of having a reliable and fast boat, the two characteristics that navigators always look for when they have to leave for a challenge like the one that awaits us from November 6, as well as all those to follow.

We are very satisfied with the results we have achieved so far. After many months of commitment and hard work, we have finally put into the water a boat that has all the credentials to ensure a very high performance and to be highly competitive”, commented Giorgio Pisani, Vice President Southern Europe IBSA and Project Leader. “The Class40 IBSA is the result of an approach that represents our way of being: it brings together innovation, attention to detail, continuous improvement and determination, with a vision that for IBSA always goes beyond the pharmaceutical field and beyond care.

With this launch, the countdown to the start of the Route du Rhum has officially begun: in the coming days Alberto Bona and the team will continue working on the boat and will begin a series of targeted training sessions, in some cases working together with other teams registered in the regatta, in a series of joint tests. In mid-September, Bona will participate in the Malouine Lamotte regatta and then, on September 22, he will attend the opening day of the Genoa Boat Show, with the aim of promoting the project Sailing into the Future. Together in all its aspects, in particular that related to social inclusion.

Indeed, in its sailing programme IBSA is also committed in the field of inclusive sailing, with the involvement of prestigious yacht clubs: the Associazione Velabili, based at the Circolo Velico Lago di Lugano (Switzerland); the Société des Régates d’Antibes (France); and the Yacht Club Punta Ala (Italy). The project – which aims to support inclusive sailing, by promoting initiatives that engage people with disabilities in experiences in contact with the sea and the world of sailing – consists in supporting a team of disabled sailors in participating in the Special Olympics World Games of 2023 and in the purchase of Hansa 303 boats for the Clubs of Punta Ala and Antibes.

IBSA

IBSA (Institut Biochimique SA) is a Swiss multinational pharmaceutical Company, founded in 1945 in Lugano. Today, its products are present in over 90 Countries on 5 continents, through the Company’s 17 subsidiaries located in Europe, China, and the United States. The company has a consolidated turnover of 800 million CHF, and employs over 2,000 people between headquarters, subsidiaries and production sites. IBSA holds 90 families of approved patents, plus others under development, as well as a vast portfolio of products, covering 10 therapeutic areas: reproductive medicine, endocrinology, pain and inflammation, osteoarticular, aesthetic medicine, dermatology, uro-gynaecology, cardiometabolic, respiratory, consumer health. It is also one of the largest operators worldwide in the area of reproductive medicine, and one of the world’s leaders in hyaluronic acid-based products. IBSA has based its philosophy on four pillars: Person, Innovation, Quality and Responsibility.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

FOR INFORMATION TO THE PRESS
IBSA Press Office – Italy
Martina Baldazzi martina.baldazzi@noesis.net – mob: +39 339 222 9911
Valeria Riccobono – valeria.riccobono@noesis.net – mob: +39 392 9625892
Ornella Reccia – ornella.reccia@noesis.net – mob: +39 329 393 1922

IBSA Press Office – Switzerland
Francesca Rossini – notizie@laboratoriodelleparole.net – mob: +41 77 417 93 72

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release

2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye